Sacrosidase is a naturally-occurring gastrointestinal enzyme derived from baker’s yeast (*Saccharomyces cerevisiae*) which breaks down the disaccharide sucrose to its monosaccharide components. Hydrolysis is necessary to allow absorption of these nutrients.

**Pre-Authorization Criteria:**

**Congenital sucrase-isomaltase deficiency:** Oral replacement therapy in sucrase deficiency, as seen in congenital sucrase-isomaltase deficiency (CSID)

**NOTE:** VCHCP requires that Sacrosidase be prescribed by a physician specializing in the condition being treated.

**NOTE:** Sucraid® is not available in retail pharmacies or via mail-order pharmacies. To obtain the product, please refer to [http://www.sucraid.net/how-to-order-sucraid](http://www.sucraid.net/how-to-order-sucraid) or call 1-866-740-2743.

**Dosing:**

**Adult:**

**Congenital sucrase-isomaltase deficiency (CSID):** Oral: 17,000 units (2 mL) per meal or snack. Doses should be diluted with 2-4 oz of cold or room temperature water, milk, or formula. Approximately one-half of the dose should be taken before and the remainder of a dose taken during each meal or snack.

**Pediatric:**

**Congenital sucrase-isomaltase deficiency (CSID):**

- **Infants ≥5 months and Children ≤15 kg:** Oral: 8500 units (1 mL) per meal or snack. Doses should be diluted with 2-4 oz of cold or room temperature water, milk, or formula. Approximately one-half of the dose should be taken before and the remainder of a dose taken during each meal or snack.
- **Children >15 kg and Adolescents:** Refer to adult dosing.

**NOTE:** Dilute dose in 2-4 oz of cold or room temperature water, milk, or formula; avoid fruit juices or warm or hot food/liquids (may lower potency).
**Dosage Forms: U.S.**
Solution, Oral: Sucraid: 8500 units/mL (118 mL) [contains papain; 50% glycerol]

**Adverse Reactions:**
Headache, insomnia, nervousness, dehydration, abdominal pain, constipation, diarrhea, nausea, vomiting.

**Contraindications:**
Hypersensitivity to yeast, yeast products, glycerin (glycerol) or papain

**References:**

**Revision History:**
Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD
Date Approved by P&T Committee: 1/27/15
Date Reviewed/No Updates: 1/26/16 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/26/16
Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/24/17
Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/23/18
Date Reviewed/No Updates: 1/22/19 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/22/19
Date Reviewed/No Updates: 2/18/20 by H. Taekman, MD; R. Sterling, MD
Date Approved by P&T Committee: 2/18/20
Date Reviewed/No Updates: 2/2/21 by H. Taekman, MD; R. Sterling, MD
Date Approved by P&T Committee: 2/2/21
Date Reviewed/Updated: 8/3/21 by H. Taekman, MD; R. Sterling, MD

S:\2023\DRUGS POLICIES\VCHCP
Date Approved by P&T Committee: 8/3/21
Date Reviewed/No Updates: 2/1/22 by H. Taekman, MD; R. Sterling, MD
Date Approved by P&T Committee: 2/1/22
Date Reviewed/No Updates: 1/31/23 by H. Taekman, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/31/23

<table>
<thead>
<tr>
<th>Revision Date</th>
<th>Content Revised (Yes/No)</th>
<th>Contributors</th>
<th>Review/Revision Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/24/17</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>1/23/18</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>1/22/19</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>2/18/20</td>
<td>No</td>
<td>Howard Taekman, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>2/2/21</td>
<td>No</td>
<td>Howard Taekman, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>8/3/21</td>
<td>Yes</td>
<td>Howard Taekman, MD; Robert Sterling, MD</td>
<td>Formatting changes</td>
</tr>
<tr>
<td>2/1/22</td>
<td>No</td>
<td>Howard Taekman, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>1/31/23</td>
<td>No</td>
<td>Howard Taekman, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
</tbody>
</table>